Neogen Reports Q1 EPS of $0.08 on Revenue of $222.8M, Surpassing Estimates
Question
Neogen Reports Q1 EPS of $0.08 on Revenue of $222.8M, Surpassing Estimates
Direct answer
Food and animal safety testing provider Neogen delivered first-quarter fiscal 2026 results that beat Wall Street consensus expectations. Total revenue expanded 6.5% year-over-year to $222.8 million, exceeding the $208.09 million estimate. Adjusted earnings per share reached $0.08, beating the $0.05 forecast by 60%. Performance was supported by sustained volume growth across Food Safety testing product lines. — bullish pressure on NEOG.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-07
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Neogen Reports Q1 EPS of $0.08 on Revenue of $222.8M, Surpassing Estimates”, revision 1, evidence through 2026-10-07. https://marketontology.com/catalysts/2026-10-07/neogen-reports-q1-eps-of-0-08-on-revenue-of-222-8m-surpassing-estimates-a8fccc
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| NEOG | ▲Bull | 1–5 days | Catalyst Driven | 60 |
Neogen Reports Q1 EPS of $0.08 on Revenue of $222.8M, Surpassing Estimates
Food and animal safety testing provider Neogen delivered first-quarter fiscal 2026 results that beat Wall Street consensus expectations. Total revenue expanded 6.5% year-over-year to $222.8 million, exceeding the $208.09 million estimate. Adjusted earnings per share reached $0.08, beating the $0.05 forecast by 60%. Performance was supported by sustained volume growth across Food Safety testing product lines. — bullish pressure on NEOG.
Food and animal safety testing provider Neogen delivered first-quarter fiscal 2026 results that beat Wall Street consensus expectations. Total revenue expanded 6.5% year-over-year to $222.8 million, exceeding the $208.09 million estimate. Adjusted earnings per share reached $0.08, beating the $0.05 forecast by 60%. Performance was supported by sustained volume growth across Food Safety testing product lines.
- SummaryFood and animal safety testing provider Neogen delivered first-quarter fiscal 2026 results that beat Wall Street consensus expectations. Total revenue expanded 6.5% year-over-year to $222.8 million, exceeding the $208.09 million estimate. Adjusted earnings per share reached $0.08, beating the $0.05 forecast by 60%. Performance was supported by sustained volume growth across Food Safety testing product lines.
- NEOGDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- NEOG closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- NEOG price vs. pre-event level
- NEOG volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| NEOG | Bullishagreed | 11.68 2026-10-07 | +0.26% | Pending | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-07Neogen Q1 Revenue Rises 6.5% to $222.8M, Surpassing Consensus EPS EstimatesNEOG+0.26%
- 2026-10-07Neogen posts Q1 earnings beat with revenue up 6.5% YoY to $222.8M and EPS of $0.08NEOG+0.26%
- 2026-10-07Neogen Delivers Q1 Revenue of $222.8M and $0.08 EPS, Exceeding ConsensusNEOG+0.26%
- 2026-10-07Neogen beats Q1 estimates with 60% EPS surprise on Food Safety expansionNEOG+0.26%
- 2026-10-07Neogen Q1 EPS Tops Consensus by 60% as Revenue Reaches $222.8MNEOG+0.26%
- 2026-10-07Neogen Reports Q1 Earnings Beat with 6.5% Revenue Growth to $222.8MNEOG+0.26%
- 2026-10-07Neogen Q1 Revenue Rises 6.5% to $222.8M, Beating Consensus ForecastsNEOG+0.26%
- 2026-10-07Neogen posts Q1 earnings beat with revenue up 6.5% YoY to $222.8M and EPS of $0.08NEOG+0.26%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.